Measurement of the Clinical and Radiological Performance Impact of the Root Canal Treatment With BioRootTM RCS.

Sponsor
Septodont (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05247138
Collaborator
(none)
142
11
64.4
12.9
0.2

Study Details

Study Description

Brief Summary

The aim of this retro-prospective Post-Market Clinical Follow-Up (PMCF) study is to collect long term clinical and safety data on root canal obturation after treatment, or retreatment, by BioRootTM RCS. The patients included in the study had received BioRootTM RCS 5 years ago. Participants will be followed prospectively at 5 and 10 years after root canal treatment.

Clinical data, radiographic data, adverse events (safety) and device performance will be collected by the dentist from the inclusion visit until the end of the study.

Condition or Disease Intervention/Treatment Phase
  • Device: BioRootTM RCS

Study Design

Study Type:
Observational
Anticipated Enrollment :
142 participants
Observational Model:
Other
Time Perspective:
Other
Official Title:
Measurement of the Clinical and Radiological Performance Impact of the Root Canal Treatment With BioRootTM RCS: a Retro-prospective, National and Multicentre Clinical Study
Actual Study Start Date :
Feb 18, 2022
Anticipated Primary Completion Date :
Oct 30, 2022
Anticipated Study Completion Date :
Jul 1, 2027

Outcome Measures

Primary Outcome Measures

  1. Clinical and radiological performance impact of the endodontic treatment at 5 years. [At 5 years post treatment]

    The "success" and "failure" of the 5-year clinical and radiological performance impact of the endodontic treatment.

Secondary Outcome Measures

  1. Clinical and radiological performance impact of the endodontic treatment at 10 years. [At 10 years post treatment]

    The "success" and "failure" of the 10-year clinical and radiological performance impact of the endodontic treatment. Absence of pain Absence of clinical evidence of infection, inflammation or swelling Normal periodontal ligament space (PAI score ≤ 2) • "failure" of the endodontic treatment occur if the investigational tooth met one of the following criteria: had been extracted for endodontic reasons since the root canal filling Had been retreated since the root canal filling Had undergone a periapical surgery since the root canal treatment Presence of pain Presence of clinical evidence of infection, inflammation or swelling PAI score ≥ 3

  2. Evaluation of the need of treatment or retreatment at 5 and 10 years. [At 5 and 10 Years post treatment]

    "The "success" and "failure" of the endodontic treatment at 5 and 10 years according treatment or retreatment.

  3. Assessment of the "tooth functional retention" at 5 and 10 years. [At 5 and 10 Years post treatment]

    The success and failure of the "tooth functional retention" at 5 and 10 years after Root Canal Treatment with BioRoot™ RCS.

  4. The technical characteristics of the sealer BioRootTM RCS at 5 and 10 years after Root Canal Treatment. [At 5 and 10 Years post treatment]

    The technical characteristics of the sealer BioRootTM RCS at 5 and 10 years after Root Canal Treatment "Not resorbable once hardened", "Not retractable over the years" and "Radiopaque" will be evaluated in patients with retro-alveolar radiographs at the follow-up consultation (in parallel of the baseline consultation). The technical characteristics are defined as follows: no resorption of the filling cement in the root, detectable on radiography dense and homogeneous filling, limited to the canal a filling with the maintenance of the canal anatomy

  5. The ease of use and insertion of BioRootTM RCS in the canal. [At 5 years post treatment]

    The ease of use and insertion of BioRootTM RCS in the canal will be evaluated with the score obtained on the Visual Analog Scale: score from 0 (Not at all) to 10 (Certainly Yes).

  6. The Investigator overall satisfaction of the experience with BioRootTM RCS. [At 5 and 10 Years post treatment]

    The Investigator overall satisfaction of the experience with BioRootTM RCS will be evaluated at 5 and 10 years after Root Canal Obturation with the score obtained on the Visual Analog Scale: score from 0 (Not at all) to 10 (Certainly Yes).

  7. The post-obturation adverse device effects. [At baseline visit, 5 and 10 years post treatment]

    The post-obturation adverse device effects will be evaluated with the list of adverse events occurring between the date of the root canal filling and the 5-year visit and between the 5-year visit and the 10-year visit.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Patient, male or female, > 18 years of age at the time of inclusion in the study.

  • Patient who had a non-surgical root canal treatment with BioRootTM RCS, in a context of an endodontic treatment, or retreatment, 5 years (± 6 months) ago.

  • All roots of the investigational teeth were treated with BioRootTM RCS.

  • Having a documented retro-alveolar radiography immediately after root canal obturation.

  • Patient affiliated or beneficiary of a social security system.

  • Patient has signed his/her informed consent form.

Exclusion Criteria:
  • History of malignant tumors in the 5 years prior to the root canal treatment.

  • Non-stabilized systemic disease during the month prior to the root canal treatment (diabetes, hypertension, thyroid disorders, etc.).

  • Patient who developed a systemic pathology after the root canal treatment with BioRootTM RCS.

  • The Root canal treatment with BioRootTM RCS is on a wisdom tooth.

  • Tooth presenting an advanced periodontal disease (parodontal pocket ≥ 5mm or bone loss ≥ 50%).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cabinet Dentaire Levallois-Perret Perret France 92300
2 Cabinet dentaire Dijon France 21000
3 Cabinet Dentaire Muizon France 51140
4 Cabinet dentaire Muizon France 51140
5 Cabinet dentaire Paris France 75006
6 Cabinet dentaire Paris France 75009
7 Cabinet dentaire Plerin France 22190
8 Cabinet dentaire Saint-Amand-sur-Sèvre France 79700
9 Cabinet dentaire Sezanne France 51120
10 Cabinet dentaire Sézanne France 51120
11 Cabinet Medical Villiers-sur-Marne France 94350

Sponsors and Collaborators

  • Septodont

Investigators

  • Study Director: Brigitte Grosgogeat, MD, PhD, CHU de Lyon, France

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Septodont
ClinicalTrials.gov Identifier:
NCT05247138
Other Study ID Numbers:
  • BIOR 2021-04
First Posted:
Feb 18, 2022
Last Update Posted:
Jun 16, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Septodont

Study Results

No Results Posted as of Jun 16, 2022